In 2022, over 24k Aussie males were diagnosed with prostate cancer. One of the most commonly diagnosed cancers, it was also the third most common cause of cancer death in Australia in 2020. Its high prevalence and the cocktail of concerns that come with it have prompted the need for better diagnosis mechanisms than the
Read MoreIn 2018, breast cancer was the most commonly diagnosed cancer in Australia. A position it held until 2022. What’s more? Its occurrence has risen, with over two million cases detected annually worldwide. Breast cancer could be fatal if not detected early—being the fifth most common cause of cancer-related death. That’s where genetic risk assessment company
Read MoreExpectant parents in Europe will soon have access to leading prenatal testing kits that are widely utilised in Australia to diagnose a range of life quality impacting diseases, including Down Syndrome, courtesy of biotech company Genetic Technologies (ASX: GTG) expanding their test kit distribution into Europe. Mothers-to-be typically perform a Non-Invasive Prenatal Test (NIPT) any
Read MoreThe one-size-fits-all approach to medicine is on its way out with the rise of personalised medicine. The development of technologies to individualise healthcare for each person holds much promise for tackling disease treatment and prevention. A prime example of this is the development of genetic testing for the BRCA genes. Inherited genetic mutations within these
Read MoreWith 1 in 8 Australians suffering from depression, the market for antidepressants is a growing one but one which medical professionals can be assisted to navigate through Genetic Technologies (ASX: GTG) and pharmacogenomics, genomic-based artificial intelligence. The tech will be coming to Australia through a new 3-year distribution agreement with Israel-based Taliaz, the developers of
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.